Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
Keywords:conjunctivitis, dupilumab, dupilumab-associated ocular surface disease, DAOSD
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface disease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.4%) developed dupilumab-associated ocular surface disease. Multivariate analysis showed a statistically significant association of the development of dupilumab-associated ocular surface disease with a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at the start of dupilumab (odds ratio 5.16, 95% confidence interval 2.30–11.56, p < 0.001). In conclusion, a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at baseline was associated with the development of dupilumab-associated ocular surface disease in patients with atopic dermatitis.
de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 2018; 178: 1083-1101.
Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81: 143-151.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.
Ariens LF, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000-1009.
Olesen CM, Holm JG, Norreslet LB, Serup JV, Thomsen SF, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 2019; 33: 1562-1568.
Popiela MZ, Barbara R, Turnbull AMJ, Corden E, Martinez-Falero BS, O'Driscoll D, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond) 2021; 35: 3277-3284.
Bohner A, Topham C, Strunck J, Haynes D, Brazil M, Clements J, et al. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea 2021; 40: 584-589.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181: 459-473.
Ariens LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy 2020; 75: 116-126.
Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 2018; 154: 1208-1211.
Uchida H, Kamata M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, et al. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting. J Am Acad Dermatol 2020; 82: 1247-1249.
Nettis E, Bonzano L, Patella V, Detoraki A, Trerotoli P, Lombardo C, et al. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol 2020; 30: 201-204.
Touhouche AT, Cassagne M, Berard E, Giordano-Labadie F, Didier A, Fournie P, et al. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol 2021; 35: 172-179.
Achten R, Bakker D, Ariens L, Lans A, Thijs J, van der Schaft J, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 2021; 9: 1389-1392.e2.
Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316-1321.
Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol 2018; 178: 1220.
Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol 2017; 77: 280-286.e1.
Simonetti O, Radi G, Diotallevi F, Molinelli E, Rizzetto G, Offidani A. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single centre experience. Clin Exp Dermatol 2021; 46: 939-940.
Harrell Jr FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis: Springer; 2015.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Strat Soc 1995; 57: 289-300.
Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009; 9: 447-453.
Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part I: associated ocular diseases. Am J Clin Dermatol 2019; 20: 797-805.
Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part II: ocular disease secondary to treatments. Am J Clin Dermatol 2019; 20: 807-815.
Dogru M, Nakagawa N, Tetsumoto K, Katakami C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol 1999; 43: 53-57.
Dogru M, Katakami C, Nakagawa N, Tetsumoto K, Yamamoto M. Impression cytology in atopic dermatitis. Ophthalmology 1998; 105: 1478-1484.
How to Cite
Copyright (c) 2022 Roselie E. Achten, Chantal M. van Luijk, Lisa P. van der Rijst, Daphne S. Bakker, Lotte S. Spekhorst, Nicolaas P. A. Zuithoff, Marie L. A. Schuttelaar, Geertruida L. E. Romeijn, Angelique N. Voorberg, Marijke Kamsteeg, Inge M. Haeck, Marlies de Graaf, Judith L. Thijs, Joke H. de Boer, Marjolein S. de Bruin-Weller
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.